Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 03:32PM ET
137.20
Dollar change
-2.00
Percentage change
-1.44
%
IndexS&P 500 P/E32.68 EPS (ttm)4.20 Insider Own0.41% Shs Outstand292.12M Perf Week1.97%
Market Cap40.21B Forward P/E22.47 EPS next Y6.11 Insider Trans-11.59% Shs Float291.84M Perf Month-5.74%
Income1.24B PEG4.06 EPS next Q1.19 Inst Own92.71% Short Float1.35% Perf Quarter5.72%
Sales6.74B P/S5.97 EPS this Y1.15% Inst Trans-3.29% Short Ratio2.48 Perf Half Y25.48%
Book/sh21.12 P/B6.50 EPS next Y10.95% ROA11.30% Short Interest3.95M Perf Year-0.92%
Cash/sh5.96 P/C23.00 EPS next 5Y8.05% ROE20.95% 52W Range96.80 - 151.58 Perf YTD-1.32%
Dividend Est.0.94 (0.69%) P/FCF24.38 EPS past 5Y33.93% ROI13.95% 52W High-9.49% Beta1.12
Dividend TTM0.92 (0.67%) Quick Ratio2.04 Sales past 5Y7.00% Gross Margin54.54% 52W Low41.74% ATR (14)3.58
Dividend Ex-DateApr 01, 2024 Current Ratio2.68 EPS Y/Y TTM-5.40% Oper. Margin23.91% RSI (14)44.19 Volatility2.91% 2.18%
Employees18100 Debt/Eq0.44 Sales Y/Y TTM-2.81% Profit Margin18.35% Recom2.43 Target Price150.54
Option/ShortYes / Yes LT Debt/Eq0.43 EPS Q/Q-0.13% Payout21.48% Rel Volume0.65 Prev Close139.20
Sales Surprise4.45% EPS Surprise5.31% Sales Q/Q-5.58% EarningsApr 18 AMC Avg Volume1.60M Price137.20
SMA20-2.96% SMA50-2.72% SMA2008.39% Trades Volume972,676 Change-1.44%
Date Action Analyst Rating Change Price Target Change
Apr-05-24Upgrade Stifel Hold → Buy $145 → $163
Dec-13-23Initiated Wolfe Research Outperform $140
Dec-12-23Downgrade BofA Securities Buy → Neutral $130 → $133
Nov-17-23Downgrade UBS Buy → Neutral $163 → $125
Sep-28-23Initiated Bernstein Mkt Perform $123
Jul-31-23Downgrade Evercore ISI Outperform → In-line $126 → $124
May-24-23Reiterated Wells Fargo Overweight $170 → $160
May-24-23Reiterated TD Cowen Outperform $168 → $145
May-24-23Reiterated SVB Securities Outperform $170 → $145
May-24-23Reiterated Stifel Hold $153 → $135
Apr-18-24 04:30PM
Apr-16-24 08:00AM
Apr-15-24 08:00AM
Apr-09-24 11:37PM
12:02PM
10:41AM Loading…
10:41AM
Apr-05-24 09:55AM
Apr-04-24 08:00AM
Apr-03-24 08:00AM
Apr-02-24 11:15AM
08:00AM
Apr-01-24 08:00AM
Mar-29-24 09:30AM
Mar-28-24 11:30AM
Mar-27-24 05:01PM
02:00AM Loading…
Mar-26-24 02:00AM
Mar-14-24 08:00AM
Mar-12-24 05:00PM
Mar-06-24 09:30AM
12:01AM
Mar-05-24 02:21PM
Mar-04-24 07:45PM
Feb-29-24 08:00AM
Feb-28-24 04:21PM
12:53PM
10:03AM
09:36AM
09:21AM
08:07AM
Feb-27-24 09:27PM
06:58PM Loading…
06:58PM
06:00PM
05:20PM
04:32PM
04:15PM
04:05PM
Feb-26-24 12:23PM
Feb-22-24 11:33AM
09:15AM
05:12AM
Feb-21-24 04:45PM
04:25PM
04:20PM
04:12PM
Feb-20-24 06:15PM
Feb-14-24 06:15PM
Feb-13-24 10:11AM
Feb-08-24 06:15PM
08:00AM
Feb-07-24 11:20AM
Feb-05-24 06:30AM
Feb-02-24 06:15PM
06:27AM
Jan-31-24 07:00AM
Jan-30-24 11:07AM
08:00AM
Jan-29-24 09:26AM
Jan-26-24 06:15PM
Jan-25-24 12:29PM
Jan-22-24 03:35PM
Jan-17-24 12:58PM
Jan-16-24 08:00AM
Jan-09-24 05:21AM
Jan-05-24 10:29AM
Dec-28-23 08:51PM
Dec-22-23 05:23AM
Dec-21-23 01:02AM
Dec-20-23 11:30AM
08:58AM
Dec-18-23 10:01AM
Dec-16-23 07:01AM
Dec-14-23 03:17PM
Dec-09-23 03:05AM
Dec-07-23 09:46AM
08:00AM
Dec-06-23 02:46AM
Dec-04-23 08:00AM
Nov-21-23 05:12PM
04:14PM
03:42PM
01:20PM
12:35PM
12:12PM
12:00PM
11:08AM
10:02AM
07:33AM
Nov-20-23 07:28PM
06:00PM
04:41PM
04:22PM
04:05PM
02:49PM
11:56AM
07:52AM
Nov-19-23 06:33PM
Nov-17-23 11:59AM
Nov-16-23 11:01AM
09:21AM
Nov-15-23 06:15PM
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binns PhilipSenior Vice PresidentMar 25 '24Sale147.542,827417,0969,997Mar 27 01:29 PM
McMullen Michael R.CEO and PresidentMar 08 '24Sale150.0052,2977,844,550253,909Mar 12 02:37 PM
Gonsalves RodneyV.P., Corporate ControllerMar 07 '24Sale149.004,828719,34821,329Mar 08 12:05 PM
FIELDS HEIDIDirectorMar 05 '24Sale144.341,658239,31654,976Mar 07 10:38 AM
Binns PhilipSenior Vice PresidentDec 27 '23Sale139.782,880402,56612,824Dec 28 01:46 PM
Gonsalves RodneyV.P., Corporate ControllerDec 18 '23Sale137.691,500206,53826,133Dec 19 02:34 PM
Ancher-Jensen HenrikSr Vice PresidentDec 15 '23Option Exercise111.3611,7031,303,235108,835Dec 19 02:33 PM
Ancher-Jensen HenrikSr Vice PresidentDec 15 '23Sale138.3626,3313,643,15782,504Dec 19 02:33 PM
McMullen Michael R.CEO and PresidentDec 13 '23Option Exercise42.122,751115,872308,957Dec 15 05:08 PM
McMullen Michael R.CEO and PresidentDec 13 '23Sale130.002,751357,630306,206Dec 15 05:08 PM
McMullen Michael R.CEO and PresidentDec 07 '23Option Exercise42.1262,4672,631,110368,673Dec 08 02:59 PM
McMullen Michael R.CEO and PresidentDec 07 '23Sale130.0062,4678,120,710306,206Dec 08 02:59 PM
Gonsalves RodneyV.P., Corporate ControllerSep 28 '23Buy111.09328824,222Sep 29 04:03 PM
Gonsalves RodneyV.P., Corporate ControllerAug 23 '23Sale118.783,500415,71624,219Aug 25 12:53 PM
McMullen Michael R.CEO and PresidentJul 27 '23Option Exercise42.1294439,761261,813Jul 31 03:03 PM
McMullen Michael R.CEO and PresidentJul 27 '23Sale130.00944122,720260,869Jul 31 03:03 PM